about Minh-Ha T. Do, Ph.D.:
Minh-Ha Do is Director of Pre-Clinical Innovation at Lumos Pharma. Dr. Do previously played dual roles as Program Scientific Lead and Associate Director of Physiology at a biotechnology company called aTyr Pharma. There, she was responsible for defining the scientific strategy to drive multiple drug development projects from discovery phase into early clinical development. Her functional roles included oversight of pre-clinical pharmacology, pharmacokinetics and toxicology and she represented these functions in interactions with the FDA and other regulatory agencies. She worked on therapeutics for cancer and rare hematopoietic and inflammatory diseases.
Before joining aTyr, Dr. Do was completing her doctoral research focused on regulation of translation in pituitary gonadotropes, where she discovered a novel pathway of mRNA regulation by gonadotropin-releasing hormone. One of her research articles was selected for a cover illustration and issue feature in a peer-reviewed journal.
Dr. Do graduated Magna Cum Laude from the University of California, Los Angeles with a B.S. degree in Molecular, Cell, and Developmental Biology. She completed her Ph.D. in Biomedical Sciences at the University of California, San Diego.